Gene therapy and custom goggles restore partial vision in some blind patients in 10-person trial

Days after the science behind it won a Nobel Prize, an experimental treatment combining a gene injection with specially designed goggles has partially restored visual function in some people with advanced blindness — the most detailed evidence yet that the approach, called optogenetic therapy, can work in more than one patient.

Results from a 10-person trial, published October 7 in The New England Journal of Medicine, show that seven participants became more sensitive to light after treatment, six of them by a margin the researchers considered clinically meaningful. Four of the eight who completed behavioral testing were consistently better at detecting, locating, and touching objects while wearing the goggles — tasks like finding a notebook on a table, locating a doorway, or following a line on the floor.

No participant regained the ability to read or recognize faces. But the findings extend a 2021 proof-of-concept study involving a single patient — whose results are included in the current group — and represent the first time the effect has been reproduced across several people.

This is a proof of concept that optogenetics can bring back some visual activity [and] object sensitivity.— Botond Roska, neuroscientist, Institute of Molecular and Clinical Ophthalmology Basel

All 10 participants had advanced retinitis pigmentosa, a group of inherited disorders in which mutations — in any of more than 100 different genes — gradually destroy the retina's light-sensing photoreceptor cells, often beginning with night vision and peripheral sight before progressing to near-total blindness. According to The Guardian, the disease is estimated to affect more than 1.5 million people around the world.

The treatment sidesteps the genetic complexity of the disease entirely. Rather than trying to fix whichever gene is broken, it recruits a different class of retinal cells — ganglion cells, which normally relay visual signals toward the brain and deteriorate more slowly than photoreceptors — and gives them a new ability to respond to light.

Into the worse-seeing eye of each participant, doctors administered a single injection. The injection used a modified, harmless synthetic virus to deliver genetic instructions for producing ChrimsonR, a light-sensitive protein derived from algae, into those surviving ganglion cells. Once the protein is expressed, the cells become sensitive to amber light.

The gene therapy delivers a light sensor to the blind retina, making it light-sensitive again. The goggles provide light stimulation at the wavelength to which this sensor responds.— José-Alain Sahel and Botond Roska, lead authors

The goggles do the second half of the work. A camera captures changes in brightness in the scene in front of the wearer; a processor converts those changes into patterns of amber light; and a projector directs those patterns onto the treated retina, activating the ChrimsonR protein. The result is a monochrome, low-resolution perception of the visual world — enough, for some participants, to find a door or reach for an object.

Training mattered. In object-detection tests, participants who logged more hours practicing with the goggles tended to score better, a pattern the researchers said points to rehabilitation as a potentially important element of the therapy.

Brain recordings from five selected participants showed signals consistent with visual information reaching the brain's visual areas — four of those five had already shown improvement in behavioral tests. The researchers noted a caveat: for some estimates, the confidence interval extended to zero.

Ophthalmologist José-Alain Sahel of the University of Pittsburgh and vision researcher Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel in Switzerland led the trial. It was funded by GenSight Biologics, which also helped design the trial and managed the data. The trial was not randomized and had no control arm — standard limitations for an early-phase safety study of this kind.

Safety was the trial's primary goal, and the researchers concluded the treatment was safe within the limits of the small study. Among nine participants, 34 eye-related adverse events were recorded, most of them mild or moderate. Seven developed inflammation inside the eye that resolved with treatment and left no lasting consequences. A blockage of the central retinal artery — classified as a severe eye event — occurred immediately after injection but cleared within minutes following medication. Separately, 70 systemic adverse events were recorded, six of them severe; after review by the principal investigator and a data and safety monitoring board, none of the systemic events were attributed to the gene therapy or the injection.

Safety was very good and is not a limitation.— José-Alain Sahel and Botond Roska, lead authors

The therapy has a structural limitation that will shape who can benefit from it: it requires a working optic nerve to carry signals from the retina to the brain. Co-author Sahel told Science News that when that connection is damaged, the therapy is unable to bring back vision. The treated ganglion cells also sit in a ring-like arrangement around the fovea — the part of the retina responsible for sharp central vision — which is why face recognition and reading remain out of reach for now.

What is still missing is the ability to recognize faces and to read; greater sensitivity of the optogenetic sensor would also be valuable. We are working to address these limitations.— José-Alain Sahel and Botond Roska, lead authors

Roska said the aim is now to work toward restoring high-resolution vision, with the hope of achieving that goal in five to ten years, according to The Guardian.

The timing of the publication was notable: the results appeared just two days after optogenetics — the broader technique of using light to switch nerve cells on and off — was awarded the 2026 Nobel Prize in Physiology or Medicine.

We've gone from one patient to 10 patients, we've seen improvement in their light sensitivity … and we've seen that we can give a stable restoration of some visual function, some light sensitivity, that lasts for four or five years in these patients. They're baby steps, but they're critical.— Mark Hankins, Professor of Visual Neuroscience, University of Oxford

Stefan Futterknecht, second author of the study, said the results 'provide a foundation for developing more sensitive and effective future therapies,' according to EurekAlert. Of the participants, four completed five years of follow-up, several others were monitored for periods ranging from two to four and a half years, and two left the study before its conclusion.

Why it matters — For the more than 1.5 million people worldwide with retinitis pigmentosa — and potentially others with degenerative blindness — this trial offers the first multi-patient evidence that a gene-and-goggles approach can safely and durably restore some ability to navigate the world, while also mapping the clear limits that researchers must now overcome.

Reported by sciencealert.com, theguardian.com, sciencenews.org, eurekalert.org, news-medical.net, uclahealth.org